Intelligence · Clinical pipeline
Oncology · Phase II
Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.
Quick answer
Oncology Phase II programs: NovaPharmaNews indexes 2,637 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
- First People's Hospital 261 programs
- Chinese Academy of 198 programs
- George Institute for 118 programs
- United Therapeutics Europe 112 programs
- Telethon Foundation 91 programs
- Takeda 79 programs
- Regeneron UK 71 programs
- MSD Merck Sharp 63 programs
- Ningbo Cancer Hospital 62 programs
- Anaxis Pharma 57 programs
- AstraZeneca 52 programs
- HOFFMANN-LA ROCHE 50 programs
Pipeline programs
-
BreAK CRC 001
Lacuna Pharma Pty Ltd
Unresectable locally advanced or metastatic colorectal cancer
1 trial -
Brentuximab Vedotin
Takeda
Enteropathy Associated T-cell Lymphoma
1 trial -
Brentuximab Vedotin
United Therapeutics Europe Ltd
Ann Arbor Stage IB Hodgkin Lymphoma
1 trial -
Brentuximab Vedotin in Combination with Tislelizumab
Takeda
NK/T Cell Lymphoma Nos
1 trial -
Brentuximab vedotin
Takeda
Relapsed or Refractory Hodgkin Lymphoma
1 trial -
BrentuximabVedotin (BV)
Takeda
Hodgkin Lymphoma
1 trial -
BrigaPED ITCC-098
AXIM BIOTECHNOLOGIES, INC.
Anaplastic Large Cell Lymphoma (ALCL), Inflammatory Myofibroblastic Tumors (IMT), Other solid tumors
1 trial -
Brigatinib
Takeda
Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma
1 trial -
Brigatinib
Takeda
Lymphoma, Large-Cell, Anaplastic
1 trial -
Brigatinib
Takeda
Anaplastic Large Cell Lymphoma, ALK-Positive
1 trial -
Brigatinib
Takeda
Carcinoma, Non-Small-Cell Lung
1 trial -
Budenofalk 4 mg Zäpfchen, placebo to test
Dr. Falk Pharma GmbH
Acute radiation proctitis symptoms in male patients aged 18 years or older with prostate carcinoma
1 trial -
Busulfan
Children's Hospital of Fudan University
Juvenile Myelomonocytic Leukemia
1 trial -
C-145-04
Iovance Biotherapeutics B.V.
Recurrent, metastatic, or persistent Cervical Carcinoma
1 trial -
C225 (cetuximab)
The First People's Hospital of Lianyungang
Nasopharyngeal Carcinoma
1 trial -
C3651003
Pfizer Australia Pty Ltd
Cancer cachexia
1 trial -
C4161001
Pfizer Australia Pty Ltd
Breast Cancer, Ovarian Cancer, SCLC (Part 1 also had TNBC and NSCLC)
1 trial -
C4221008
Pfizer Australia Pty Ltd
Non-small Cell Lung Cancer
1 trial -
C4221022
Pfizer Australia Pty Ltd
MSI-H/dMMR metastatic colorectal cancer
1 trial -
C4221023
Pfizer Australia Pty Ltd
Metastatic or unresectable locally advanced BRAF V600E/K mutation positive melanoma
1 trial -
C4391025
Pfizer Australia Pty Ltd
HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER
1 trial -
C4971006
Pfizer Australia Pty Ltd
Relapsed/Refractory Diffuse Large B Cell Lymphoma
1 trial -
C6461008
Pfizer Australia Pty Ltd
ADVANCED OR METASTATIC RENAL CELL CARCINOMA
1 trial -
C6461013
Pfizer Australia Pty Ltd
Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma
1 trial -
CA001-044
Bristol-Myers Squibb Australia Pty Ltd
Extensive-Stage Small Cell Lung Cancer
1 trial -
CA001-050
Bristol-Myers Squibb Australia Pty Ltd
Extensive-stage Small Cell Lung Cancer
1 trial -
CA027-002
Bristol-Myers Squibb Australia Pty Ltd
Advanced solid tumors
1 trial -
CA043-001
Bristol-Myers Squibb Australia Pty Ltd
Advanced solid tumors (squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), cutaneous melanoma, triple-negative breast cancer (TNBC), renal cell carcinoma (RCC), urothelial carcinoma, gastric, esophageal, cervical, and colorectal cancer (CRC)).
1 trial -
CA0471009
Bristol-Myers Squibb Australia Pty Ltd
Non-small Cell Lung Cancer
1 trial -
CA073-1022
Celgene Europe Limited
Newly Diagnosed Advanced Stage Follicular Lymphoma
1 trial -
CA082-1215
Bristol-Myers Squibb Australia Pty Ltd
Primary Central Nervous System Lymphoma
1 trial -
CA116-001
Bristol-Myers Squibb Australia Pty Ltd
Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
1 trial -
CA126-0015
Bristol-Myers Squibb Australia Pty Ltd
Oncology, NSCLC and CRC
1 trial -
CA180-226
Bristol-Myers Squibb Australia Pty Ltd
Children and Adolescents with Newly Diagnosed Chronic Phase CML or with Ph+ Leukemias Resistant to or Intolerant to Imatinib
1 trial -
CA209-032
Bristol-Myers Squibb Australia Pty Ltd
Advanced or metastatic solid tumors: 1) Triple Negative Breast Cancer (TNBC) 2) Gastric Cancer (GC) 3) Pancreatic Cancer (PC) 4) Small Cell Lung Cancer (SCLC). 5) Bladder Cancer (BC) 6) Ovarian Cancer (OC)
1 trial -
CA209-142
Bristol-Myers Squibb Australia Pty Ltd
MSI Negative Colorectal Cancer, MSI Positive Colorectal Cancer
1 trial -
CA209-1533
Bristol-Myers Squibb Australia Pty Ltd
Non-small cell lung cancer (NSCLC)
1 trial -
CA209-6E8, CNN-BC
Fondazione Telethon ETS
Patients with non-metastatic muscle invasive bladder cancer
1 trial -
CA209-8TT
Bristol-Myers Squibb Australia Pty Ltd
Pan tumor
1 trial -
CA224-020
Bristol-Myers Squibb Australia Pty Ltd
Neoplasms by site
1 trial -
CA224-048
Bristol-Myers Squibb Australia Pty Ltd
Advanced Malignant Tumors
1 trial -
CA224-104
Bristol-Myers Squibb Australia Pty Ltd
Non small Cell Lung cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer
1 trial -
CA224-1044
Bristol-Myers Squibb Australia Pty Ltd
Melanoma
1 trial -
CA224-106
Bristol-Myers Squibb Australia Pty Ltd
Advanced/metastatic hepatocellular carcinoma (HCC)
1 trial -
CA2360001
Bristol-Myers Squibb Australia Pty Ltd
Advanced Solid Tumors
1 trial -
CA244-0001
Bristol-Myers Squibb Australia Pty Ltd
Advance solid tumors
1 trial -
CA258-0001
Bristol-Myers Squibb Australia Pty Ltd
Relapsed/Refractory Small Cell Lung Cancer
1 trial -
CA2660006
Bristol-Myers Squibb Australia Pty Ltd
Advanced or unresectable Hepatocellular Carcinoma (HCC)
1 trial
Frequently asked questions
How many oncology Phase II programs exist?
2,637 programs match both the therapeutic area and stage filters in our published index.